Anzeige
Mehr »
Login
Donnerstag, 10.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
NEWS-HAMMER bei JERICHO ENERGY! KI-Partnerschaft mit AT&T
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 871275 | ISIN: US2394671034 | Ticker-Symbol: DX5
Berlin
10.04.25
08:21 Uhr
7,300 Euro
+1,100
+17,74 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
DAXOR CORPORATION Chart 1 Jahr
5-Tage-Chart
DAXOR CORPORATION 5-Tage-Chart

Aktuelle News zur DAXOR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:22Daxor reicht neuen Blutvolumen-Analysator bei der FDA ein1
14:18Daxor submits new blood volume analyzer to FDA1
DAXOR Aktie jetzt für 0€ handeln
14:06Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer2
02.04.Daxor's BVA technology gains traction at cardiology event2
02.04.Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo5
28.03.Daxor Corporation: Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks1
04.03.Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024101Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the...
► Artikel lesen
04.03.Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders1
04.03.Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023121Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the...
► Artikel lesen
28.02.Daxor Corporation: Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center1
19.02.Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 20252
14.02.Daxor Corporation: Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment3
13.02.Daxor Hikeson Blood Study-
13.02.Daxor Corporation: New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care1
18.12.24Daxor Corporation: Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum2
03.09.24Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter153Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update...
► Artikel lesen
05.06.24Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer162Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1